Symbols / BRTX
BRTX Chart
About
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.29M |
| Enterprise Value | -2.08M | Income | -12.67M | Sales | 383.40K |
| Book/sh | 0.28 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | — | Forward P/E | -0.23 | PEG | — |
| P/S | 16.40 | P/B | 0.98 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | -5.43 | Quick Ratio | 1.31 |
| Current Ratio | 1.37 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.46 | EPS next Y | -1.17 | EPS Growth | — |
| Revenue Growth | -94.90% | Earnings | 2025-11-12 17:00 | ROA | -89.73% |
| ROE | -207.73% | ROIC | — | Gross Margin | 93.34% |
| Oper. Margin | -314.32% | Profit Margin | 0.00% | Shs Outstand | 23.33M |
| Shs Float | 8.05M | Short Float | 1.74% | Short Ratio | 5.69 |
| Short Interest | — | 52W High | 2.28 | 52W Low | 0.21 |
| Beta | 0.24 | Avg Volume | 1.50M | Volume | 217.93M |
| Target Price | $9.50 | Recom | Strong_buy | Prev Close | $0.20 |
| Price | $0.27 | Change | 37.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$0.27
Latest analyst target
3. DCF / Fair value
$-5.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.27
Low
$1.00
High
$18.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-14 | main | Roth MKM | Buy → Buy | $18 |
| 2024-06-12 | main | Roth MKM | Buy → Buy | $15 |
| 2023-08-14 | reit | Roth MKM | Buy → Buy | $15 |
| 2022-12-07 | init | Roth Capital | — → Buy | $15 |
| 2022-09-28 | init | Maxim Group | — → Buy | $6 |
| 2021-12-01 | init | Roth Capital | — → Buy | $37 |
- Australia clears patent for cell therapy touted as GLP-1 alternative - Stock Titan ue, 24 Feb 2026 13
- BioRestorative Therapies Receives Positive FDA Feedback on BRTX-100 Program for Accelerated BLA Approval Pathway - Quiver Quantitative Wed, 11 Feb 2026 08
- BioRestorative Announces Closing of $5.0 Million Public Offering - GlobeNewswire Fri, 13 Feb 2026 08
- 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga Fri, 20 Feb 2026 17
- BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook - simplywall.st Wed, 05 Nov 2025 08
- BioRestorative Therapies stock plunges after $5 million public offering - Investing.com South Africa hu, 12 Feb 2026 14
- Market Movers | Winners: HCTI, ATPC, ANY | Losers: QVCGA, BRTX, IVDA - Trefis Wed, 11 Feb 2026 04
- Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛 hu, 19 Feb 2026 13
- BioRestorative Closes $5 Million Public Offering of 14.3 Million Shares - Intellectia AI Sat, 14 Feb 2026 01
- Stem cell developer BioRestorative seeks $5M for BRTX-100 trials - Stock Titan Wed, 11 Feb 2026 08
- BioRestorative Therapies stock falls after $1.1M registered offering - Investing.com Mon, 06 Oct 2025 07
- BioRestorative Announces Pricing of Public Offering - Intellectia AI hu, 12 Feb 2026 08
- 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga Wed, 11 Feb 2026 17
- FDA meeting outlines expedited approval path for BioRestorative BRTX-100 - Stock Titan Wed, 11 Feb 2026 08
- 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga hu, 12 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11719 | 18750 | — | Stock Award(Grant) at price 1.60 per share. | SILVA FRANCISCO | Officer and Director | — | 2025-10-06 00:00:00 | D |
| 1 | 15625 | 25000 | — | Stock Award(Grant) at price 1.60 per share. | ALSTODT LANCE | Chief Executive Officer | — | 2025-10-06 00:00:00 | D |
| 2 | 1112 | 1757 | — | Sale at price 1.58 per share. | BROADRICK DALE | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-28 00:00:00 | D |
| 3 | 8308 | 10229 | — | Purchase at price 1.13 - 1.25 per share. | SILVA FRANCISCO | Officer and Director | — | 2024-04-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.18M | -18.97M | -24.27M | -26.22M |
| TotalUnusualItems | 1.81M | 4.00M | 5.52M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.81M | 4.00M | 5.52M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.98M | -10.42M | -13.22M | -44.30M |
| ReconciledDepreciation | 189.06K | 165.74K | 120.55K | 89.11K |
| ReconciledCostOfRevenue | 28.07K | 0.00 | ||
| EBITDA | -11.37M | -14.97M | -18.74M | -26.22M |
| EBIT | -11.56M | -15.14M | -18.86M | -26.31M |
| NetInterestIncome | 616.08K | 552.29K | 11.65K | -1.82M |
| InterestExpense | 1.82M | |||
| InterestIncome | 616.08K | 552.29K | 11.65K | |
| NormalizedIncome | -10.79M | -14.42M | -18.74M | -44.30M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.98M | -10.42M | -13.22M | -44.30M |
| TotalExpenses | 11.96M | 15.28M | 18.98M | 26.35M |
| TotalOperatingIncomeAsReported | -11.56M | -15.22M | -18.97M | -26.31M |
| DilutedAverageShares | 7.76M | 4.22M | 3.62M | 1.19M |
| BasicAverageShares | 7.76M | 4.22M | 3.62M | 1.19M |
| DilutedEPS | -1.16 | -2.47 | -3.65 | -37.30 |
| BasicEPS | -1.16 | -2.47 | -3.65 | -37.30 |
| DilutedNIAvailtoComStockholders | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeCommonStockholders | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncome | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeIncludingNoncontrollingInterests | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeContinuousOperations | -8.98M | -10.42M | -13.22M | -44.30M |
| PretaxIncome | -8.98M | -10.42M | -13.22M | -44.30M |
| OtherIncomeExpense | 1.96M | 4.17M | 5.63M | -16.18M |
| OtherNonOperatingIncomeExpenses | 150.85K | 169.66K | 107.09K | -16.18M |
| SpecialIncomeCharges | 0.00 | 250.00K | 0.00 | |
| OtherSpecialCharges | -250.00K | |||
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 1.81M | 4.00M | 5.27M | |
| NetNonOperatingInterestIncomeExpense | 616.08K | 552.29K | 11.65K | -1.82M |
| TotalOtherFinanceCost | -11.65K | 1.82M | ||
| InterestExpenseNonOperating | 1.82M | |||
| InterestIncomeNonOperating | 616.08K | 552.29K | 11.65K | |
| OperatingIncome | -11.56M | -15.14M | -18.86M | -26.31M |
| OperatingExpense | 11.93M | 15.28M | 18.98M | 26.35M |
| OtherOperatingExpenses | -83.33K | -110.52K | ||
| ResearchAndDevelopment | 5.35M | 4.03M | 3.51M | 729.06K |
| SellingGeneralAndAdministration | 6.58M | 11.33M | 15.58M | 25.62M |
| SellingAndMarketingExpense | 12.29K | |||
| GeneralAndAdministrativeExpense | 6.58M | 11.33M | 15.58M | 25.62M |
| OtherGandA | 6.58M | 11.33M | 15.58M | 25.62M |
| GrossProfit | 372.93K | 145.80K | ||
| CostOfRevenue | 28.07K | 0.00 | ||
| TotalRevenue | 401.00K | 145.80K | 119.80K | 46.00K |
| OperatingRevenue | 401.00K | 145.80K | 119.80K | 46.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| PreferredSharesNumber | 1.54M | 1.40M | 1.52M | |
| OrdinarySharesNumber | 6.92M | 4.71M | 3.68M | 3.52M |
| ShareIssued | 6.92M | 4.71M | 3.68M | 3.52M |
| TotalDebt | 0.00 | 162.32K | 301.64K | 670.70K |
| TangibleBookValue | 7.89M | 9.28M | 9.47M | 20.99M |
| InvestedCapital | 8.52M | 9.99M | 10.28M | 21.83M |
| WorkingCapital | 7.40M | 8.78M | 9.15M | 21.10M |
| NetTangibleAssets | 7.91M | 9.29M | 9.49M | 21.01M |
| CapitalLeaseObligations | 0.00 | 162.32K | 301.64K | 420.70K |
| CommonStockEquity | 8.52M | 9.99M | 10.28M | 21.58M |
| PreferredStockEquity | 13.98K | 13.98K | 15.18K | 15.43K |
| TotalCapitalization | 8.53M | 10.00M | 10.29M | 21.79M |
| TotalEquityGrossMinorityInterest | 8.53M | 10.00M | 10.29M | 21.60M |
| StockholdersEquity | 8.53M | 10.00M | 10.29M | 21.60M |
| RetainedEarnings | -155.68M | -146.70M | -136.28M | -134.15M |
| AdditionalPaidInCapital | 164.20M | 156.69M | 146.56M | 155.73M |
| CapitalStock | 14.67K | 14.45K | 15.55K | 15.79K |
| CommonStock | 692.00 | 471.00 | 369.00 | 353.00 |
| PreferredStock | 13.98K | 13.98K | 15.18K | 15.43K |
| TotalLiabilitiesNetMinorityInterest | 3.75M | 2.61M | 6.14M | 856.50K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 162.32K | 492.68K |
| LongTermDebtAndCapitalLeaseObligation | 162.32K | 492.68K | ||
| LongTermCapitalLeaseObligation | 0.00 | 162.32K | 301.64K | |
| LongTermDebt | 191.03K | |||
| CurrentLiabilities | 3.75M | 2.61M | 5.98M | 363.82K |
| OtherCurrentLiabilities | 2.52M | 1.54M | 5.54M | |
| CurrentDebtAndCapitalLeaseObligation | 162.32K | 139.33K | 178.03K | |
| CurrentCapitalLeaseObligation | 0.00 | 162.32K | 139.33K | 119.06K |
| CurrentDebt | 58.97K | |||
| OtherCurrentBorrowings | 58.97K | |||
| PayablesAndAccruedExpenses | 1.23M | 901.08K | 300.97K | 185.80K |
| CurrentAccruedExpenses | 744.49K | 711.69K | 130.07K | 134.97K |
| Payables | 483.07K | 189.39K | 170.90K | 50.83K |
| AccountsPayable | 483.07K | 189.39K | 170.90K | 50.83K |
| TotalAssets | 12.28M | 12.61M | 16.43M | 22.45M |
| TotalNonCurrentAssets | 1.14M | 1.22M | 1.31M | 985.54K |
| NonCurrentDeferredAssets | 148.70K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 623.95K | 713.69K | 803.44K | 589.74K |
| OtherIntangibleAssets | 623.95K | 713.69K | 803.44K | 589.74K |
| NetPPE | 362.94K | 507.50K | 502.76K | 395.80K |
| AccumulatedDepreciation | -1.11M | -1.01M | -935.84K | -893.63K |
| GrossPPE | 1.47M | 1.52M | 1.44M | 1.29M |
| Leases | 342.05K | 342.05K | 342.05K | 304.66K |
| OtherProperties | 853.55K | 898.81K | 594.99K | 740.65K |
| MachineryFurnitureEquipment | 278.47K | 278.47K | 259.81K | 244.11K |
| BuildingsAndImprovements | 151.45K | 241.76K | ||
| CurrentAssets | 11.14M | 11.39M | 15.13M | 21.47M |
| OtherCurrentAssets | 223.23K | 305.23K | 363.08K | 436.18K |
| PrepaidAssets | 436.18K | |||
| Receivables | 188.40K | 19.30K | 16.00K | 5.00K |
| AccountsReceivable | 188.40K | 19.30K | 16.00K | 5.00K |
| CashCashEquivalentsAndShortTermInvestments | 10.73M | 11.07M | 14.75M | 21.03M |
| OtherShortTermInvestments | 10.18M | 10.18M | 13.04M | 0.00 |
| CashAndCashEquivalents | 547.89K | 884.38K | 1.71M | 21.03M |
| CashFinancial | 21.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.34M | -6.60M | -6.35M | -3.36M |
| IssuanceOfDebt | 0.00 | 250.00K | ||
| IssuanceOfCapitalStock | 0.00 | 2.35M | 0.00 | 21.07M |
| CapitalExpenditure | -106.19K | -171.04K | -440.22K | -30.66K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 547.89K | 884.38K | 1.71M | 21.03M |
| BeginningCashPosition | 884.38K | 1.71M | 21.03M | 3.06M |
| ChangesInCash | -336.49K | -829.39K | -19.31M | 17.96M |
| FinancingCashFlow | 7.38M | 2.35M | 0.00 | 21.32M |
| CashFlowFromContinuingFinancingActivities | 7.38M | 2.35M | 0.00 | 21.32M |
| NetOtherFinancingCharges | -148.70K | |||
| ProceedsFromStockOptionExercised | 7.53M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 2.35M | 0.00 | 21.07M |
| CommonStockIssuance | 0.00 | 2.35M | 0.00 | 21.07M |
| NetIssuancePaymentsOfDebt | 0.00 | 250.00K | ||
| NetLongTermDebtIssuance | 0.00 | 250.00K | ||
| LongTermDebtIssuance | 0.00 | 250.00K | ||
| InvestingCashFlow | 514.53K | 3.25M | -13.40M | -30.66K |
| CashFlowFromContinuingInvestingActivities | 514.53K | 3.25M | -13.40M | -30.66K |
| NetInvestmentPurchaseAndSale | 620.72K | 3.42M | -12.96M | 0.00 |
| SaleOfInvestment | 21.51M | 20.96M | 9.49M | |
| PurchaseOfInvestment | -20.89M | -17.54M | -22.45M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -175.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -175.00K | 0.00 | |
| NetPPEPurchaseAndSale | -106.19K | -171.04K | -265.22K | -30.66K |
| PurchaseOfPPE | -106.19K | -171.04K | -265.22K | -30.66K |
| OperatingCashFlow | -8.23M | -6.43M | -5.91M | -3.33M |
| CashFlowFromContinuingOperatingActivities | -8.23M | -6.43M | -5.91M | -3.33M |
| ChangeInWorkingCapital | 28.65K | 515.33K | 14.14K | 324.69K |
| ChangeInOtherCurrentLiabilities | -162.32K | -139.33K | -163.13K | -101.19K |
| ChangeInPayablesAndAccruedExpense | 326.48K | 600.10K | 115.18K | 744.65K |
| ChangeInAccruedExpense | 32.80K | 581.62K | -4.90K | 812.67K |
| ChangeInInterestPayable | 812.67K | |||
| ChangeInPayable | 293.68K | 18.49K | 120.08K | -68.02K |
| ChangeInAccountPayable | 293.68K | 18.49K | 120.08K | -68.02K |
| ChangeInPrepaidAssets | 33.59K | 57.85K | 73.10K | -330.77K |
| ChangeInReceivables | -169.10K | -3.30K | -11.00K | 12.00K |
| ChangesInAccountReceivables | -169.10K | -3.30K | -11.00K | 12.00K |
| OtherNonCashItems | 151.45K | 90.31K | -89.88K | 1.27M |
| StockBasedCompensation | 2.81M | 7.78M | 12.61M | 23.11M |
| UnrealizedGainLossOnInvestmentSecurities | -33.66K | 0.00 | ||
| DepreciationAmortizationDepletion | 189.06K | 165.74K | 120.55K | 89.11K |
| DepreciationAndAmortization | 189.06K | 165.74K | 120.55K | 89.11K |
| AmortizationCashFlow | 89.75K | 89.75K | 78.33K | |
| AmortizationOfIntangibles | 89.75K | 89.75K | 78.33K | |
| Depreciation | 99.31K | 75.99K | 42.21K | |
| OperatingGainsLosses | -2.43M | -4.57M | -5.35M | 16.18M |
| GainLossOnInvestmentSecurities | -2.43M | -4.57M | -5.35M | |
| NetIncomeFromContinuingOperations | -8.98M | -10.42M | -13.22M | -44.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|